Alzheimer's disease
Although the prevalence of dementia continues to increase worldwide, incidence in the
western world might have decreased as a result of better vascular care and improved brain …
western world might have decreased as a result of better vascular care and improved brain …
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Executive summary Alzheimer's disease (AD) is the leading cause of dementia, and
because the primary risk factor for AD is old age, the prevalence of the disease is increasing …
because the primary risk factor for AD is old age, the prevalence of the disease is increasing …
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease
See Sarazin et al.(doi: 10.1093/brain/aww041) for a scientific commentary on this article.
The advent of the positron emission tomography tracer 18 F-AV1451 provides the unique …
The advent of the positron emission tomography tracer 18 F-AV1451 provides the unique …
Impairments of neural circuit function in Alzheimer's disease
MA Busche, A Konnerth - Philosophical Transactions of …, 2016 - royalsocietypublishing.org
An essential feature of Alzheimer's disease (AD) is the accumulation of amyloid-β (Aβ)
peptides in the brain, many years to decades before the onset of overt cognitive symptoms …
peptides in the brain, many years to decades before the onset of overt cognitive symptoms …
Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI
Objective: To examine the clinical and biomarker characteristics of patients with amyloid-
negative Alzheimer disease (AD) and mild cognitive impairment (MCI) from the Alzheimer's …
negative Alzheimer disease (AD) and mild cognitive impairment (MCI) from the Alzheimer's …
Cerebrospinal fluid Alzheimer's disease biomarkers across the spectrum of Lewy body diseases: results from a large multicenter cohort
I Van Steenoven, D Aarsland… - Journal of …, 2016 - content.iospress.com
Background: Concomitant Alzheimer's disease (AD) pathology is observed in Lewy body
diseases (LBD), but the clinical impact is unknown. Only a few biomarker studies in LBD …
diseases (LBD), but the clinical impact is unknown. Only a few biomarker studies in LBD …
Assessment of the incremental diagnostic value of florbetapir F 18 imaging in patients with cognitive impairment: the incremental diagnostic value of amyloid PET with …
M Boccardi, D Altomare, C Ferrari, C Festari… - JAMA …, 2016 - jamanetwork.com
Importance Cerebral amyloidosis is a key abnormality in Alzheimer disease (AD) and can be
detected in vivo with positron emission tomography (PET) ligands. Although amyloid PET …
detected in vivo with positron emission tomography (PET) ligands. Although amyloid PET …
Propagation of Aß pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies
YS Eisele, C Duyckaerts - Acta neuropathologica, 2016 - Springer
In brains of patients with Alzheimer's disease (AD), Aβ peptides accumulate in parenchyma
and, almost invariably, also in the vascular walls. Although Aβ aggregation is, by definition …
and, almost invariably, also in the vascular walls. Although Aβ aggregation is, by definition …
Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease
G Chételat, R Ossenkoppele, VL Villemagne… - Brain, 2016 - academic.oup.com
Abstract See O'Sullivan and Vann (doi: 10.1093/aww166) for a scientific commentary on this
article. About 15% of patients clinically diagnosed with Alzheimer's disease do not show …
article. About 15% of patients clinically diagnosed with Alzheimer's disease do not show …
Accelerated decline in white matter integrity in clinically normal individuals at risk for Alzheimer's disease
Prior studies have identified white matter abnormalities in Alzheimer's disease (AD). Yet,
cross-sectional studies in normal older individuals show little evidence for an association …
cross-sectional studies in normal older individuals show little evidence for an association …